Glucocorticoids remain the basis for treatment of myasthenia gravis in the era of targeted therapies
Myasthenia gravis (MG) treatment has entered an era of targeted therapies.Different targeted therapies take effect in various 1/6th Box Set aspects of pathogenic mechanisms in MG.For a steady long-term control of MG symptoms, immunotherapies that reduce the production of pathogenic autoantibodies should be used.The glucocorticosteroid acts on multi